Elbasvir/grazoprevir administered for 12 weeks via Percutaneous Endoscopic Gastrostomy Tube Achieves Sustained Virologic Response: A Case Report and a Review of the Literature

This report describes the first case of a pegylated‐interferon and ribavirin treatment‐experienced patient who successfully achieved HCV cure after 12 weeks of elbasvir/grazoprevir administered via percutaneous gastrostomy tube. We further review the available pharmacokinetic and clinical literature regarding administration via enteral feeding tubes for all first‐line direct acting antivirals (DAAs). The literature suggests that cr ushed administration can be considered for DAAs in patients with gastric access. However, caution should be exercised in patients with extragastric enteral tubes and in those with altered gastrointestinal tract anatomy.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: CASE REPORT Source Type: research